Nicholas L. Teti, Jr. Appointed President and CEO of Suneva Medical

SAN DIEGO, CA – October 15, 2010 – Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of industry veteran Nicholas L. Teti, Jr. to President and CEO. Mr. Teti has twenty-five years experience in the pharmaceutical industry and ten years in the aesthetics space, most notably as the President and CEO of Inamed Corporation. Niv Caviar, the current President and CEO, has decided to pursue other opportunities. Mr. Teti will continue to serve as Chairman of the Board.

Todd Davis, Vice Chairman of Suneva, commented, “Nick has decades of industry experience and a proven leadership track record of growing companies. His expertise is critical to take Suneva to the next level of corporate growth and we are excited to have him join the senior management team.”

He continued, “We thank Niv for his commitment to re-launch Artefill into the U.S. marketplace. This has given us a platform to accelerate the Company forward.”

Mr. Teti commented, “The prospects for both Suneva and Artefill are excellent and I am honored to lead the organization through this exciting period of growth. Our teams are focused on four core areas as we look ahead to 2011 – expand the number of indications for Artefill, establish an international franchise to extend the brand globally, identify complementary products to add under the Suneva umbrella and most importantly deliver our customers the highest level of service and support. These are key drivers of our growth strategy and we are confident that we will make significant strides in each area in the months ahead.”

Nicholas Teti has served on the Board of Directors of Suneva since April 2009 and as Chairman since July 2010. He was previously CEO of Isolagen, Inc., a biotechnology company which develops emergent, novel skin and tissue rejuvenation technologies. From 2001 to 2006, Mr. Teti was President and Chief Executive Officer of Inamed Corporation, a healthcare products manufacturer focused on marketing breast implants, dermal fillers to correct facial wrinkles, and devices to treat severe and morbid obesity, including the LAP-BAND Adjustable Gastric Banding System. He served on the board of Inamed in 2001 and was Chairman of the Board from 2002 to 2006 through the Allergan acquisition. Prior to Inamed, Mr. Teti spent twenty-five years at DuPont and DuPont Merck where he held a number of senior management positions including President and CEO of DuPont Pharmaceuticals. He currently serves on the Board of Enteromedics.

About Suneva Medical

Suneva Medical, Inc. is a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The Company’s lead product is Artefill®, the first and only microsphere-enhanced collagen filler for the correction of nasolabial folds, or smile lines. For more information visit sunevamedical.com/old.

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.